Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The employee equity awards vest over four annual installments, with continued service required at each vesting date.

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) granted two new employees restricted stock units representing 25,000 common shares on November 2, 2026.

The Compensation Committee approved the awards under the 2023 Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted stock units are awards tied to company shares. They vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to each employee's continued service through the applicable vesting date.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.25,000 common shares underlying new employee restricted stock units represent potential dilution as awards vest.

Key Figures

RSU grant: 25,000 shares Vesting schedule: Four equal annual installments

RSU grant

25,000 shares

Aggregate award to two new employees

Vesting schedule

Four equal annual installments

Subject to continued service through each vesting date

Key Terms

restricted stock units, adeno-associated virus, monogenic diseases, rett syndrome

4 terms

restricted stock units financial

"granted two new employees, in the aggregate, restricted stock units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

adeno-associated virus technical

"adeno-associated virus (AAV)-based gene therapies"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

monogenic diseases medical

"gene therapies for severe monogenic diseases of the central nervous system"

A monogenic disease is a medical condition caused by a harmful change in a single gene, where that single faulty instruction is enough to produce symptoms. For investors, these diseases matter because their clear genetic cause can make it easier for drug developers to design targeted therapies, diagnostics, or gene therapies, creating distinct clinical pathways, regulatory considerations, and potentially more predictable commercial opportunities—like fixing one broken line of code in a program.

rett syndrome medical

"TSHA-102 is in development for Rett syndrome"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Company’s common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
investors@tayshagtx.com  

Media Contact:
media@tayshagtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many restricted stock units did Taysha Gene Therapies grant to new employees?

Taysha granted two new employees restricted stock units representing an aggregate of 25,000 common shares on November 2, 2026. The awards were granted under the company's 2023 Inducement Plan as a material inducement to entering employment.

When do Taysha Gene Therapies' November 2026 employee equity awards vest?

The awards vest in four equal annual installments, beginning on the first anniversary of the award's vesting commencement date. Each installment requires the employee to remain in service with Taysha through that vesting date.